| |
| |
|
| Insider
Information: |
Karbe Frank |
| Relationship: |
Director |
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
846,802 |
|
|
Indirect Shares
|
11,849 |
|
|
| Direct
Value |
$7,722,741 |
|
|
|
Indirect Value
|
$248,711 |
|
|
| Total
Shares |
858,651 |
|
|
| Total
Value |
$7,971,452 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
3
|
3
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
3
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
-3.0
|
-3.0
|
| Percentage
Gain/Loss : |
 -82.8%
|
-4.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Exelixis Inc |
EXEL |
EVP and CFO |
2014-02-15 |
93,990 |
2014-02-15 |
11,849 |
Premium* |
|
|
Tekmira Pharmaceuticals Corp |
TKMR |
Director |
2015-01-01 |
5,000 |
|
0 |
Premium* |
|
|
Myovant Sciences Ltd. |
MYOV |
Principal Finl & Accou... |
2021-07-07 |
212,296 |
2019-06-11 |
0 |
Premium* |
|
|
Better Therapeutics |
BTTX |
|
2023-12-18 |
526,516 |
2022-09-15 |
0 |
Premium* |
|
|
Phathom Pharmaceuticals, Inc. |
PHAT |
Director |
2023-05-25 |
9,000 |
2023-05-25 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
63 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| TKMR |
Tekmira Pharmaceuticals C... |
Director |
– • – |
2015-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,000 |
|
- |
|
| MYOV |
Myovant Sciences Ltd. |
Principal Finl & Accounting |
• – – |
2021-01-28 |
4 |
OE |
$5.11 |
$1,533 |
D/D |
300 |
163,770 |
0 |
- |
|
| MYOV |
Myovant Sciences Ltd. |
Principal Finl & Accounting |
• – – |
2021-01-28 |
4 |
AS |
$24.00 |
$7,200 |
D/D |
(300) |
163,470 |
0 |
% |
|
| MYOV |
Myovant Sciences Ltd. |
Principal Finl & Accounting |
• – – |
2020-12-15 |
4 |
AS |
$23.63 |
$8,980 |
D/D |
(380) |
164,140 |
0 |
% |
|
| MYOV |
Myovant Sciences Ltd. |
Principal Finl & Accounting |
• – – |
2020-12-15 |
4 |
AS |
$24.45 |
$16,383 |
D/D |
(670) |
163,470 |
0 |
% |
|
| MYOV |
Myovant Sciences Ltd. |
Principal Finl & Accounting |
• – – |
2020-08-19 |
4 |
OE |
$5.11 |
$3,577 |
D/D |
700 |
164,170 |
0 |
- |
|
| MYOV |
Myovant Sciences Ltd. |
Principal Finl & Accounting |
• – – |
2020-08-19 |
4 |
AS |
$20.00 |
$14,000 |
D/D |
(700) |
163,470 |
0 |
% |
|
| EXEL |
Exelixis Inc |
EVP and CFO |
• – – |
2012-05-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(716) |
75,407 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP and CFO |
• – – |
2012-08-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(716) |
76,644 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP and CFO |
• – – |
2012-11-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(716) |
80,751 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP and CFO |
• – – |
2013-08-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(733) |
90,515 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP and CFO |
• – – |
2013-11-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(733) |
92,893 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP and CFO |
• – – |
2013-05-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(735) |
89,295 |
0 |
- |
|
| MYOV |
Myovant Sciences Ltd. |
Principal Finl & Accounting |
• – – |
2020-09-15 |
4 |
OE |
$5.11 |
$3,833 |
D/D |
750 |
164,220 |
0 |
- |
|
| MYOV |
Myovant Sciences Ltd. |
Principal Finl & Accounting |
• – – |
2020-09-15 |
4 |
AS |
$21.73 |
$16,298 |
D/D |
(750) |
163,470 |
0 |
% |
|
| MYOV |
Myovant Sciences Ltd. |
Principal Finl & Accounting |
• – – |
2020-11-13 |
4 |
OE |
$5.11 |
$3,833 |
D/D |
750 |
164,220 |
0 |
- |
|
| MYOV |
Myovant Sciences Ltd. |
Principal Finl & Accounting |
• – – |
2020-11-13 |
4 |
AS |
$20.00 |
$15,000 |
D/D |
(750) |
163,470 |
0 |
% |
|
| MYOV |
Myovant Sciences Ltd. |
Principal Finl & Accounting |
• – – |
2020-11-17 |
4 |
AS |
$20.00 |
$15,000 |
D/D |
(750) |
163,470 |
0 |
% |
|
| MYOV |
Myovant Sciences Ltd. |
Principal Finl & Accounting |
• – – |
2020-11-17 |
4 |
OE |
$5.11 |
$3,833 |
D/D |
750 |
164,220 |
0 |
- |
|
| MYOV |
Myovant Sciences Ltd. |
Principal Finl & Accounting |
• – – |
2021-01-15 |
4 |
AS |
$21.50 |
$16,125 |
D/D |
(750) |
163,470 |
0 |
% |
|
| MYOV |
Myovant Sciences Ltd. |
Principal Finl & Accounting |
• – – |
2021-01-15 |
4 |
OE |
$5.11 |
$3,833 |
D/D |
750 |
164,220 |
0 |
- |
|
| MYOV |
Myovant Sciences Ltd. |
Principal Finl & Accounting |
• – – |
2021-02-16 |
4 |
AS |
$21.40 |
$16,050 |
D/D |
(750) |
163,470 |
0 |
% |
|
| MYOV |
Myovant Sciences Ltd. |
Principal Finl & Accounting |
• – – |
2021-02-16 |
4 |
OE |
$5.11 |
$3,833 |
D/D |
750 |
164,220 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP and CFO |
• – – |
2014-02-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(857) |
93,990 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP and CFO |
• – – |
2013-02-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(915) |
81,789 |
0 |
- |
|
63 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
